Theraclion SAS
This article was originally published in Start Up
Executive Summary
Paris-based Theraclion SAS has developed a non-surgical approach to treating hyperparathyroidism. The company's TH-One technology employs an externally applied converging beam of high-intensity focused ultrasound to create a rapid temperature rise in the extremely small parathyroid glands. Each pulse of energy produces a small lesion of coagulation, leading to destruction of the parathyroids.